A Study to Investigate in Healthy Volunteers (Part 1) and in Patients With Type 2 Diabetes Mellitus (Part 2) the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of RO6799477

NCT02164266 | Completed Phase 1

• 2 other identifiers: BP292052014-000718-78
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

This study is designed to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of RO6799477 following once daily oral administration for 2 weeks in healthy volunteers (Part 1) and in Type 2 diabetes patients (T2D) (Part 2). The anticipated time on study treatment is two weeks.

Conditions

Healthy Volunteer, Type 2 Diabetes

Outcome Measures

Primary Outcomes (1)

• Incidence of adverse events (AEs)

  Up to 9 weeks

Secondary Outcomes (3)

• Pharmacokinetic parameters derived from plasma and urine concentrations of RO6799477, area under the concentration time curve (AUC), Cmax

  Day 1 and Day 14

• Fasting serum glucose

  Up to 9 weeks

• Fasting serum insulin (Part 2 only)

  Up to 9 weeks

Study Arms (3)

Part 1: Healthy Volunteers

EXPERIMENTAL

Drug: Placebo; Drug: RO6799477

Part 2: Patients with T2D, Group A

EXPERIMENTAL

Low dose daily oral administration of RO6799477

Drug: Placebo; Drug: RO6799477

Part 2: Patients with T2D, Group B

EXPERIMENTAL

High dose daily oral administration of RO6799477

Drug: Placebo; Drug: RO6799477

Interventions

Placebo DRUG

Matching placebo daily oral administration

Part 1: Healthy Volunteers; Part 2: Patients with T2D, Group A; Part 2: Patients with T2D, Group B

RO6799477 DRUG

Daily oral administration of RO6799477

Part 1: Healthy Volunteers; Part 2: Patients with T2D, Group A; Part 2: Patients with T2D, Group B

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Right-handed male volunteers
• Aged 18-45 years, inclusive
• Healthy participants, as determined by screening assessments and Principal Investigator's judgment
• Healthy status is defined by the absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, hematology, blood chemistry, serology and urinalysis
• Body Mass Index (BMI) of 18-30 kg/m2 inclusive, with body weight in the range of 50-100 kg
• Patients with type 2 diabetes according to WHO criteria diagnosed for at least 3 months prior to screening
• Male or female patients, 40 to 65 years of age, inclusive
• Type 2 diabetic patients who are either drug naive (diet \& exercise alone) or on a stable dose of metformin for at least 3 months prior to screening or willing to safely stop sulfonylurea medications at least 2 weeks prior to first dose administration and until follow-up visit
• BMI of 23-42 kg/m2, inclusive

You may not qualify if:

• Any clinically relevant history or the presence of e.g. respiratory, renal, hepatic, gastrointestinal, hematological, lymphatic, neurological, cardiovascular, psychiatric, etc. disease or diseases
• Disorders of central nervous system, psychiatric disorders, behavioral disturbances (e.g. cerebrovascular events, depression, post-traumatic stress disorder \[PTSD\], anxiety, bipolar disorder, severe migraine, Parkinson's disease)
• Participation in an investigational drug or device study within 3 months prior to screening or more than 4 times per year
• Concomitant disease or condition that could interfere with, or treatment of which might interfere with, the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
• Type 1 diabetes
• Acquired or secondary forms of diabetes such as those resulting from pancreatic surgery/injury, cystic fibrosis related diabetes
• Evidence or history of clinically significant diabetic complications such as clinically severe diabetic peripheral neuropathy, clinically significant nephropathy as judged by the investigator, or pre-proliferative/proliferative diabetic retinopathy as judged by the investigator or already diagnosed by the diabetologist or general practitioner
• Disorders of central nervous system, psychiatric disorders, behavioral disturbances
• Clinically significant history or presence of bronchopulmonary, gastrointestinal, hematological, lymphatic, neurological, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, infectious, connective tissue or inflammatory diseases, and any type of cancer (with the exception of treated basal cell carcinoma of the skin) or other clinically significant disease
• Use of anti-diabetic drugs other than metformin or sulfonylureas within 2 months prior to screening
• Any condition or disease detected during the medical interview / physical examination that would render the patient unsuitable for the study, place the patient at undue risk or interfere with the ability of the patient to complete the study in the opinion of the investigator

Sponsors & Collaborators

• Hoffmann-La Roche: lead

Study Sites (1)

Unknown Facility

Leiden, 2333, Netherlands

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Study Officials

• Clinical Trials

  Hoffmann-La Roche

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 6, 2014
• First Posted: June 16, 2014
• Study Start: June 1, 2014
• Primary Completion: December 1, 2014
• Study Completion: December 1, 2014
• Last Updated: June 14, 2017

Record last verified: 2017-06

Locations

NL (1)